Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA: Legal action against STADA’s Serbian subsidiary has been resolved

  • 18/12/2015
  • Ad hoc Release

Bad Vilbel, December 18, 2015 – The insolvency administrator of Velefarm Holding as well as Velefarm VFB and the Serbian Hemofarm A.D., a subsidiary of STADA Arzneimittel AG, have today, on December 18, 2015 agreed on the resolution of a legal dispute.

The settlement relates to the legal action taken by the insolvency administrator against Hemofarm, among others, in Belgrade’s commercial court in February 2014 (see ad hoc release from February 14, 2014). At that time, the insolvency administrator had demanded that certain agreements and statements from the years 2010 and 2011 that had been reached between Hemofarm and companies of the Serbian wholesale group Velefarm with regard to the insolvent assets of Velefarm Holding and Velefarm VFB be declared invalid and, as a result, repayments to the insolvent assets be made.

Within the scope of the settlement, the insolvency administrator waives his original claim in the amount of Euro 54.2 million (in local currency) which he had filed in court. In return, Hemofarm waives most of a claim in the single-digit million euro range which was already fully impaired by STADA in 2010.

“Resolution of the legal dispute, which we believed from the beginning was unfounded, confirms our previous confidence in the Serbian legal system”, says Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer at STADA Arzneimittel AG.

“In view of the high priority that our Serbian location has in the Group, it is important that the dispute has been resolved. This means that there continues to be a good basis for the successful cooperation with our Serbian colleagues”, says Hartmut Retzlaff, Chairman of the Executive Board at STADA Arzneimittel AG.

 

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]
Or visit us in the Internet at www.stada.com.